Leptomeningeal metastasis from non-small cell lung cancer: Survival and the impact of whole brain radiotherapy Journal Article


Authors: Morris, P. G.; Reiner, A. S.; Szenberg, O. R.; Clarke, J. L.; Panageas, K. S.; Perez, H. R.; Kris, M. G.; Chan, T. A.; Deangelis, L. M.; Omuro, A. M.
Article Title: Leptomeningeal metastasis from non-small cell lung cancer: Survival and the impact of whole brain radiotherapy
Abstract: Introduction: Leptomeningeal metastasis (LM), or leptomeningeal carcinomatosis, is a devastating complication of non-small cell lung cancer (NSCLC), and the optimal therapeutic approach remains challenging. A retrospective review was carried out to assess the impact of whole brain radiotherapy (WBRT), intrathecal therapy (IT), and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on outcomes. Methods: Patients with newly diagnosed LM from NSCLC from January 2002 to December 2009 were identified through institutional databases and medical records reviewed. Survival was assessed by Kaplan-Meier and landmark analyses by administered treatment to minimize selection bias. Results: We identified 125 patients (45 men, 80 women) with LM from NSCLC, median age 59 years (range, 28-87 years). Almost all (123 [98%]) patients have died and median overall survival was 3.0 months (95% confidence interval, 2.0-4.0). No differences in survival were seen between patients who were treated with WBRT (n = 46) and those who were not (n = 59, p = 0.84) in a landmark analysis. In the seven patients selected to receive IT chemotherapy, median survival was 18 months (range, 5-33 months) and appeared superior to those not selected for this treatment (p = 0.001) in a landmark analysis. The median survival of the nine patients with known EGFR mutations (all of whom received TKIs at some point) was 14 months (range, 1-28 months). Conclusions: This retrospective study, the largest published series, demonstrates the poor survival of LM from NSCLC. In this study, survival was not improved by WBRT. The survival of patients selected for IT chemotherapy and those with EGFR mutations treated with TKIs highlights the importance of developing novel agents. Copyright © 2012 by the International Association for the Study of Lung Cancer.
Keywords: radiotherapy; leptomeningeal metastasis; non-small cell; intrathecal chemotherapy; leptomeningeal carcinomatosis
Journal Title: Journal of Thoracic Oncology
Volume: 7
Issue: 2
ISSN: 1556-0864
Publisher: Elsevier Inc.  
Date Published: 2012-02-01
Start Page: 382
End Page: 385
Language: English
DOI: 10.1097/JTO.0b013e3182398e4f
PROVIDER: scopus
PUBMED: 22089116
DOI/URL:
Notes: --- - "Export Date: 2 April 2012" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Anne S Reiner
    122 Reiner
  2. Timothy Chan
    222 Chan
  3. Patrick Glyn Morris
    107 Morris
  4. Jennifer L Clarke
    11 Clarke
  5. Antonio Marcilio Padula Omuro
    177 Omuro
  6. Katherine S Panageas
    331 Panageas
  7. Mark Kris
    612 Kris